SEGMENT REPORTING (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Revenue	$ 14,745,702	$ 13,206,717	$ 28,458,230	$ 27,791,190
Cost of Sales	(13,581,888)	(12,439,469)	(25,244,617)	(25,690,316)
GROSS PROFIT	1,163,814	767,248	3,213,613	2,100,874
General and administrative expenses	(1,490,485)	(1,390,525)	(2,969,187)	(2,808,663)
Salaries	(1,868,443)	(1,454,862)	(2,908,462)	(2,713,041)
Sales and marketing expenses	(21,706)	(110,813)	(49,861)	(284,443)
Depreciation and amortization	(353,862)	(313,074)	(674,301)	(632,861)
Stock-based compensation			1,159,632	680,389
Net profit/(loss) before Income Taxes	(2,828,068)	(2,590,711)	(3,646,165)	(4,457,401)
Sales and marketing expenses	21,706	110,813	49,861	284,443
Cost of Sales	$ 13,581,888	$ 12,439,469	25,244,617	$ 25,690,316
Other [Member]
Revenue			0
Cost of Sales			0
GROSS PROFIT			0
General and administrative expenses			(638,782)
Salaries			(653,187)
Sales and marketing expenses			0
Research and development costs			(90,266)
Net finance costs			(240,855)
Segment profit / (loss)			(1,623,090)
Depreciation and amortization			(291,597)
Stock-based compensation			(1,159,632)
Foreign currency transaction, net			171,061
Other income and expenses			(164,592)
Net profit/(loss) before Income Taxes			(3,067,850)
Research and development costs			90,266
Sales and marketing expenses			0
Cost of Sales			0
Total Segment [Member]
Revenue			28,458,230
Cost of Sales			(25,244,617)
GROSS PROFIT			3,213,613
General and administrative expenses			(1,809,555)
Salaries			(2,908,462)
Sales and marketing expenses			(49,861)
Research and development costs			(90,266)
Net finance costs			(541,911)
Segment profit / (loss)			(2,186,442)
Depreciation and amortization			(674,301)
Stock-based compensation			(1,159,632)
Foreign currency transaction, net			618,348
Other income and expenses			(244,138)
Net profit/(loss) before Income Taxes			(3,646,165)
Research and development costs			90,266
Sales and marketing expenses			49,861
Cost of Sales			25,244,617
Wholesale [Member]
Revenue			26,033,751
Cost of Sales			(24,386,605)
GROSS PROFIT			1,647,146
General and administrative expenses			(322,885)
Salaries			(863,913)
Sales and marketing expenses			(855)
Research and development costs			0
Net finance costs			(421,748)
Segment profit / (loss)			37,745
Depreciation and amortization			(71,720)
Stock-based compensation			0
Foreign currency transaction, net			168,432
Other income and expenses			17,279
Net profit/(loss) before Income Taxes			151,736
Research and development costs			0
Sales and marketing expenses			855
Cost of Sales			24,386,605
Pharma manufacturing [Member]
Revenue			800,958
Cost of Sales			(138,384)
GROSS PROFIT			662,574
General and administrative expenses			(305,947)
Salaries			(725,844)
Sales and marketing expenses			(731)
Research and development costs			0
Net finance costs			0
Segment profit / (loss)			(369,948)
Depreciation and amortization			(103,556)
Stock-based compensation			0
Foreign currency transaction, net			0
Other income and expenses			(95,802)
Net profit/(loss) before Income Taxes			(569,306)
Research and development costs			0
Sales and marketing expenses			731
Cost of Sales			138,384
Nutraceuticals and Pharmaceuticals [Member]
Revenue			1,623,520
Cost of Sales			(719,627)
GROSS PROFIT			903,893
General and administrative expenses			(541,941)
Salaries			(665,518)
Sales and marketing expenses			(48,275)
Research and development costs			0
Net finance costs			120,692
Segment profit / (loss)			(231,149)
Depreciation and amortization			(207,428)
Stock-based compensation			0
Foreign currency transaction, net			278,855
Other income and expenses			(1,023)
Net profit/(loss) before Income Taxes			(160,745)
Research and development costs			0
Sales and marketing expenses			48,275
Cost of Sales			$ 719,627